Alexander B Olawaiye, Md

This study tests a combination of three drugs—ALX148, liposomal doxorubicin, and pembrolizumab—in people with recurrent ovarian cancer that no longer responds to platinum-based chemotherapy. The goal is to see if blocking the CD47 protein on cancer cells can boost the immune syst…

This study tests whether a two-drug combination can help the immune system attack ovarian cancer that has returned after standard treatments. The drugs are E7777, which removes certain immune cells that block the body's defenses, and pembrolizumab, which reactivates cancer-fighti…